Full Press Release Details
Cellectar Biosciences
to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
FLORHAM PARK, N.J., January 09, 2020 --
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development
and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday,
February 19, 2020 at 10:30 am Eastern Time.
Members of Cellectar's senior management
team and Dr. Sikander Ailawadhi, M.D., the lead investigator for the company's Phase 2 study, will provide additional clinical
data, as well as an update and analysis of the CLR 131 Phase 1 and Phase 2 hematology focused trials. The team will also provide
a summary of the data for patients with relapsed/refractory B-cell malignancies, including patients with multiple myeloma and select
non-Hodgkins lymphoma. Additionally, the team will review the current treatment landscape and unmet medical need for treating patients
with these cancers, and provide an overview of the market opportunity and its clinical development plan for CLR 131.
Sikander Ailawadhi, M.D., is an Associate
Professor, Division of Hematology/Oncology at Mayo Clinic Florida and is the lead investigator for the company's Phase 2
CLOVER-1 trial of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers. Dr. Ailawadhi was awarded the 2013 NCI
CCITLA as an Assistant Professor of Medicine at the Norris Cancer Center, University of Southern California (USC), Los Angeles
CA. Subsequently, he joined the Division of Hematology and Oncology at Mayo Clinic in Florida as a Senior Associate Consultant
in order to pursue his career goal of clinical, translational and outcomes-based research in B-cell malignancies, especially plasma
Dial-In & Webcast Information
Domestic: 877-705-6003
International: 201-493-6725
Conference ID: 13697717
A replay of the call will be available
on the Events section on the Investor Relations page of company's website following
About the Phase 2 CLOVER-1 Trial
Phase 2 study of CLR 131 being conducted in approximately 10 leading cancer centers in the United States in patients with relapsed/refractory
B-cell hematologic cancers. The hematologic cancers being studied in the trial include multiple myeloma (MM), chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma
(MCL), and diffuse large B-cell lymphoma (DLBCL).
enroll up to 80 patients. Its primary endpoint is clinical benefit response (CBR), with additional endpoints of overall response
rate (ORR), progression free survival (PFS), median overall survival (OS) and other markers of efficacy following a fractionated
dose of 37.5mCi/m2 of CLR 131 administered in two 30-minute infusions of 18.75mCi/m2 of CLR 131
administered on day 1 and day 7 ( 1), with the option for a second dose cycle approximately 75-180 days later.
awarded approximately $2 million in non-dilutive grant funding from the National Cancer Institute to help fund the trial. More
information about the trial, including eligibility requirements, can be found at www.clinicaltrials.gov,
reference NCT02952508.
The Phase 1 multicenter,
open-label, dose-escalation study is designed to evaluate the safety and tolerability of CLR 131 administered as a 30-minute IV
infusion, either as a single bolus dose or as two fractionated doses, in patients with relapsed/refractory multiple myeloma. All
doses to date have been deemed safe and well tolerated by an independent Data Monitoring Committee (DMC). Based on the data and
the recommendation of the DMC, the company is enrolling a Cohort 7 where patients will receive 40mCi/m2 fractionated
CLR 131 is a small-molecule, targeted Phospholipid
Drug Conjugate (PDC) designed to deliver cytotoxic radiation directly to cancer cells, while limiting exposure to healthy
cells. CLR 131 is the company's lead product candidate and is currently being evaluated in a Phase 2 study in B-cell lymphomas,
and two Phase 1 dose-escalating clinical studies, one in multiple myeloma and one in pediatric solid tumors and lymphoma. CLR 131
was granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission, and was
granted U.S. Orphan Drug designation for the treatment of lymphoplasmacytic lymphoma and was granted U.S. Orphan Drug and Rare
Pediatric Disease designations for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma.
Cellectar Biosciences
is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing
proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage
its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop PDCs that specifically target cancer
cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform
possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to
develop PDCs independently and through research and development collaborations.
lead PDC therapeutic, CLR 131, is currently in three clinical studies - one Phase 2 study, and two Phase 1 studies. The Phase 2
clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma
(MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with
R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphomas.
product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets.
For more information,
please visit www.cellectar.com or join the conversation by liking and following us on
the company's social media channels: Twitter, LinkedIn,
Forward-Looking Statement Disclaimer
contains forward-looking statements. You can identify these statements by our use of words such as "may", "expect",
"believe", "anticipate", "intend", "could", "estimate", "continue",
"plans", or their negatives or cognates. These statements are only estimates and predictions and are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements
made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development
involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the
ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development
thereof, the completion of clinical studies, the FDA review process and other government regulation, the volatile market for priority
review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition
from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form
10-K for the year ended December 31, 2018 and Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30,
2019. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking